Contact CFFC


Clinical Trial Alerts – October 2019

Cystic Fibrosis Foundation issued the following clinical trial alert in the month of October.

October 16, 2019

Study of VX-445 triple combination in teens and adults with cystic fibrosis who have one copy of F508del and one copy of a gating or residual function mutation

Status: Enrolling

Description: This study will look at the safety and effectiveness of three CFTR modulators when taken in combination: VX-445 (elexacaftor), tezacaftor, and ivacaftor. CFTR modulators are drugs intended to help CFTR protein function closer to normal.

Age: 12 Years and Older

Mutation: One Copy F508del

Fev1% Predicted: 40 to 90%

Number of Visits: 8

Length of Participation: 20 weeks link:

Comments are closed.